Press Releases Latest Mar 14, 2023 Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model Press Releases Year None20232022202120202019201820172016201520142013 May 18, 2021 Theratechnologies to Participate in Virtual Fireside Chat With Canaccord Genuity on May 20, 2021 May 13, 2021 Announcements in Conjunction With Theratechnologies Annual Meeting Apr 14, 2021 Theratechnologies Reports First Quarter 2021 Financial Results and Recent Business Highlights Apr 12, 2021 Theratechnologies to Present at the Bloom Burton & Co. Healthcare Investor Conference Apr 01, 2021 Theratechnologies to Announce Financial Results for Its First Quarter Fiscal 2021 Apr 10, 2021 Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types Mar 29, 2021 Theratechnologies Announces Two Strategic Hires to Support its Commercial and Pipeline Assets Mar 24, 2021 Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Mar 20, 2021 Theratechnologies Announces New Data Demonstrating Tesamorelin’s Positive Effect On Immune Response Linked To Liver Inflammation Mar 10, 2021 Theratechnologies Announces Two E-Posters on TH1902 To Be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021 First page « Previous page ‹ … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page › Last page » Displaying 61 - 70 of 305
Mar 14, 2023 Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
May 18, 2021 Theratechnologies to Participate in Virtual Fireside Chat With Canaccord Genuity on May 20, 2021
Apr 14, 2021 Theratechnologies Reports First Quarter 2021 Financial Results and Recent Business Highlights
Apr 10, 2021 Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types
Mar 29, 2021 Theratechnologies Announces Two Strategic Hires to Support its Commercial and Pipeline Assets
Mar 24, 2021 Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors
Mar 20, 2021 Theratechnologies Announces New Data Demonstrating Tesamorelin’s Positive Effect On Immune Response Linked To Liver Inflammation
Mar 10, 2021 Theratechnologies Announces Two E-Posters on TH1902 To Be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021
